Exporting active substances manufactured in Great Britain for use in EEA and Northern Ireland

AI Summary

This regulatory guidance issued by the UK Medicines and Healthcare products Regulatory Agency (MHRA) outlines the documentation requirements for the trade of active pharmaceutical substances. Under the current regulatory framework, manufacturers based in Great Britain—including England, Wales, and Scotland—must secure a Written Confirmation for every shipment exported to the European Economic Area (EEA) or Northern Ireland. This measure ensures that exported materials adhere to strict quality and safety standards. Conversely, the guidance identifies specific exemptions for imports into Great Britain. Active substances originating from Northern Ireland or a list of approved countries, including the United States, Japan, South Korea, Brazil, Australia, Israel, and Switzerland, do not require a Written Confirmation. Northern Ireland remains aligned with European Union rules regarding the placement of manufactured goods on the market. To ensure compliance, businesses must obtain the necessary documentation for outbound shipments to the EEA and verify the origin of inbound materials to determine if they meet the criteria for exemption. As this document is a general regulatory guideline, it does not specify a particular company name, inspection dates, or individual violations, but rather serves as a mandatory framework for all industry participants to maintain legal supply chain operations.